Navigation Links
The Leukemia & Lymphoma Society and Celator Pharmaceuticals Announce Partnership to Accelerate Development of CPX-351 for AML
Date:1/22/2009

WHITE PLAINS, N.Y. and PRINCETON, N.J., Jan. 22 /PRNewswire/ -- The Leukemia & Lymphoma Society (LLS) and Celator Pharmaceuticals, Inc. today announced a partnership to support Phase 2 development of Celator's lead product candidate CPX-351 (Cytarabine:Daunorubicin) Liposome Injection for treatment of adults with acute myeloid leukemia (AML).

Through the partnership, LLS will provide $3.7 million to support Celator's Phase 2B multicenter, randomized, open-label trial of CPX-351 versus intensive salvage therapy in adult patients less than or equal to 60 years of age with AML in first relapse. Celator expects to start patient enrollment in this study in the first quarter of 2009 in the United States and Canada.

The partnership between Celator and LLS is part of LLS's Therapy Acceleration Program (TAP), which supports private sector and academic-based projects with the goal of advancing investigational therapies with high prospects for providing near-term benefit to patients with blood cancers.

"Celator has discovered a novel way to deliver and enhance the activity of agents that have been the standard of care in AML for decades," said Louis DeGennaro, Ph.D., LLS's chief scientific officer. "There have been many attempts to improve outcomes in this patient population with little success. The data collected on CPX-351 to date, and the enthusiasm of clinical investigators involved in that research, suggest that Celator's approach holds real promise to advance the treatment of AML."

"We are very pleased that The Leukemia & Lymphoma Society sees the potential of CPX-351 and is making this substantial investment," said Scott Jackson, chief executive officer, Celator Pharmaceuticals. "LLS has created a well defined, streamlined process for accessing capital for promising new blood cancer treatments. This commitment enhances our ability to further the clinical development of CPX-351
'/>"/>

SOURCE Celator Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
2. CuraGen and TopoTarget Initiate Phase I/II Clinical Trial of Belinostat (PXD101) Combination Therapy for Acute Myeloid Leukemia
3. St. Jude Discovers Factors That Accelerate Resistance to Gleevec(TM) Targeted Therapy in Lymphoblastic Leukemia
4. September is Leukemia, Lymphoma and Myeloma Awareness Month
5. The Leukemia & Lymphoma Society is Encouraged by Promising News for Myeloma Patients
6. The Leukemia & Lymphoma Society and Cleveland Clinic Taussig Cancer Institute Announce Groundbreaking Partnership to Accelerate Drug Approvals
7. Leukemia Drug Proves Safe and Effective Over the Long Term
8. TREANDA Significantly Improves Clinical Outcomes in Patients with Chronic Lymphocytic Leukemia Compared to Chlorambucil
9. Preclinical Studies Show Promise for Novel Antibody Therapy to Treat Acute Myeloid Leukemia (AML)
10. Celator(R) Pharmaceuticals Reports CPX-351 Shows Anti-Cancer Activity in Leukemia Patients
11. Data Presented at 2007 ASH Meeting Demonstrate Activity of Forodesine HCl as a Single Agent or in Combination With Bendamustine in Certain Types of Leukemia and Lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... DUBLIN , June 25, 2015 ... the addition of the "Veterinary / Animal Vaccines ... to 2020" report to their offering. ... $7,197.9 Million by 2020 from $5,507.3 Million in 2015, ... Major factors fueling market growth are growing ...
(Date:7/2/2015)... July 2, 2015 Legal-Bay LLC, The Lawsuit ... Joseph Goodwin in the Southern District of ... transvaginal mesh cases against Ethicon for a single trial ... cases for the 26 women include claims from the ... made my Johnson & Johnson,s Ethicon subsidiary. The cases ...
(Date:7/2/2015)... Agreement reinforces ViiV ...   ViiV Healthcare and Desano Pharmaceuticals (Desano) today ... China of dolutegravir. The agreement will offer ... and will allow ViiV Healthcare to offer a competitive supply ... Tivicay®) for China and a number ...
Breaking Medicine Technology:Veterinary / Animal Vaccines Market 2015 - Global Forecast to 2020 for the $7.19 Billion Industry 2Judge Sets Single Trial for 26 Ethicon Mesh Cases, says Legal-Bay Lawsuit Settlement Funding 2Judge Sets Single Trial for 26 Ethicon Mesh Cases, says Legal-Bay Lawsuit Settlement Funding 3ViiV Healthcare and Desano Pharmaceuticals' Manufacturing Agreement Will Allow Competitive Supply of Dolutegravir in China and Several Developing Countries 2ViiV Healthcare and Desano Pharmaceuticals' Manufacturing Agreement Will Allow Competitive Supply of Dolutegravir in China and Several Developing Countries 3ViiV Healthcare and Desano Pharmaceuticals' Manufacturing Agreement Will Allow Competitive Supply of Dolutegravir in China and Several Developing Countries 4ViiV Healthcare and Desano Pharmaceuticals' Manufacturing Agreement Will Allow Competitive Supply of Dolutegravir in China and Several Developing Countries 5ViiV Healthcare and Desano Pharmaceuticals' Manufacturing Agreement Will Allow Competitive Supply of Dolutegravir in China and Several Developing Countries 6
... SARcode Bioscience, Inc., a privately-held biopharmaceutical company, ... enrolled in the company,s pivotal Phase 3 clinical ... (Logo: http://photos.prnewswire.com/prnh/20110718/FL36481LOGO) SAR 1118 ... by blocking the binding of two key cellular ...
... response to the growing needs of its clients, Avrio ... Hull 72FXS100-SS25C Freeze Drying System and a new M&O ... Alu-Crimp Capping Machine. The acquisition of these leading-edge technologies ... and Bosch FLT Automated Filling/Stoppering/Capping systems allow Avrio to ...
Cached Medicine Technology:First Patient Enrolled in SARcode Bioscience's Pivotal Dry Eye Study of SAR 1118 Ophthalmic Solution 2First Patient Enrolled in SARcode Bioscience's Pivotal Dry Eye Study of SAR 1118 Ophthalmic Solution 3Avrio Purchases a New Lyophilizer and Liquid Vial Filling Machine - New Capabilities and Added Capacity 2
(Date:7/2/2015)... ... July 02, 2015 , ... “ LIFX ” was featured on NewsWatch ... products available to consumers. Amanda Forstrom, a technology expert and special reporter for NewsWatch, ... versatile smart light bulbs on the market. , According to the U.S. Department of ...
(Date:7/2/2015)... PEACHTREE CITY, GA (PRWEB) , ... July 02, ... ... or field sporting the newest shades of the SIGVARIS PERFORMANCE SOCKS. Since the ... physicians, fitness experts and athletic trainers. Their significant popularity has inspired four new, ...
(Date:7/2/2015)... ... , ... Six months ahead of his 80th birthday, Don Stevenson has reached ... for the Pulmonary Hypertension Association (PHA). Stevenson began the walk in Washington State ... mid-September. He left Glasgow, Mont. yesterday morning and is making his way to Wolf ...
(Date:7/2/2015)... Diego, CA (PRWEB) , ... July 02, 2015 , ... ... and a passion for social fitness. Built to function as a lifestyle community, Active ... giving them the opportunity to network, meet, and participate in discussions or group events. ...
(Date:7/2/2015)... ... July 02, 2015 , ... ... - pipeline review 2015” provides comprehensive information on the pipeline products with ... on negative pressure wound therapy (NPWT) with 22 market data tables and ...
Breaking Medicine News(10 mins):Health News:The Most Versatile Smart Light Bulbs were featured on NewsWatch Television 2Health News:SIGVARIS is Sporting Four Brand New Colors in the Popular PERFORMANCE SOCK Product Line 2Health News:79-Year-old ‘Pacing Parson’ Passes 1,000-Mile Mark in Cross-Country Walk for Pulmonary Hypertension Association 2Health News:79-Year-old ‘Pacing Parson’ Passes 1,000-Mile Mark in Cross-Country Walk for Pulmonary Hypertension Association 3Health News:ActiveBunch.com Launches as a Social Community for People with Active Lifestyles 2Health News:Negative Pressure Wound Therapy (System, Wound Care, Tissue Cooling NPWT) Pipeline Review 2015 Market Research Report Available at RnRMarketResearch.com 2Health News:Negative Pressure Wound Therapy (System, Wound Care, Tissue Cooling NPWT) Pipeline Review 2015 Market Research Report Available at RnRMarketResearch.com 3Health News:Negative Pressure Wound Therapy (System, Wound Care, Tissue Cooling NPWT) Pipeline Review 2015 Market Research Report Available at RnRMarketResearch.com 4
... to the health threat posed by Americans, over-consumption of sodium, ... Public Health (HSPH) and The Culinary Institute of America (CIA) ... effectiveand that maximize the enjoyment people derive from food. ... sodium reduction as a critical public health priority, much as ...
... ,e-visit, using images sent via Internet, study finds , ... who had online follow-up visits with their dermatologist had ... a new study finds. , The study included 121 ... follow-up visits or four in-office visits. Every six weeks, ...
... ... Energy without the stomach issues. The Company chose four test markets to evaluate adoption ... ... Energy ™ patches are newly released to the retail market. Many health conscious adults ...
... University of Illinois have identified a potential drug target ... is embedded in the membrane of neurons and other ... activates this receptor, sparking increased activity in the affected ... The new findings appear in the FASEB Journal ...
... ... Will Participate – Savings and Valuable Incentives Are Still Available , ... (Vocus) April 20, 2010 -- Toll Brothers, the ... at communities nationwide from April 24 until May 2. With the slight rise in interest ...
... ... babies. , ... April 20, 2010 -- Building on 175 years of expertise in the care for mothers ... new , , , , ,ePhilanthropy venture dedicated to supporting healthy moms, pregnancies and babies. ...
Cached Medicine News:Health News:Experts call for accelerated national sodium reduction initiatives 2Health News:Experts call for accelerated national sodium reduction initiatives 3Health News:Experts call for accelerated national sodium reduction initiatives 4Health News:Acne Patients Happy With Online Follow-Up Care 2Health News:Peoria and Baltimore Serve as Test Markets for New Spot On Energy Product 2Health News:Team finds promising new drug target for Alzheimer's disease 2Health News:Team finds promising new drug target for Alzheimer's disease 3Health News:Spring Into A New Toll Brothers Dream Home During the National Spring Sales Event April 24 - May 2 2Health News:Spring Into A New Toll Brothers Dream Home During the National Spring Sales Event April 24 - May 2 3Health News:Spring Into A New Toll Brothers Dream Home During the National Spring Sales Event April 24 - May 2 4Health News:Brigham and Women's Hospital Launches Stork Fund 2Health News:Brigham and Women's Hospital Launches Stork Fund 3
Protein-to-creatinine ratio is key to earlier detection of Kidney Disease...
... Your basic entry to ... Urine Analyzer delivers an affordable, ... test strip evaluation. With fundamental, ... Urine Analyzer keeps physician office ...
... The Clinitek 50 analyzer is an ... smaller laboratories the reliability and consistency ... better, more efficient way to obtain ... settings demand an economy of motion ...
... dual pressure sensor catheters incorporate ... slow-speed injection/guide wire, or high-speed ... for high-speed injection has two ... and an open-end pigtail extension ...
Medicine Products: